Back to Search
Start Over
AstraZeneca
- Source :
- Chemical Market Reporter. Jan 5, 2004, Vol. 265 Issue 1, p7, 1 p.
- Publication Year :
- 2004
-
Abstract
- ASTRAZENECA submitted a new drug application (NDA) to the FDA for Exanta (ximelagatran), an investigational oral direct thrombin inhibitor. If approved, Exanta will be the first new oral anticoagulant on [...]
- Subjects :
- Lexicon Pharmaceuticals Inc. -- Licensing agreements
AstraZeneca PLC -- Licensing, certification and accreditation
AstraZeneca PLC -- Planning
AstraZeneca PLC -- Licensing agreements
Pharmaceutical industry -- Licensing, certification and accreditation
Pharmaceutical industry -- Planning
Pharmaceutical industry -- Licensing agreements
Thrush (Mouth disease) -- Care and treatment
Drug approval -- Planning
Biotechnology industry -- Licensing agreements
Company licensing agreement
Company business planning
Business
Chemicals, plastics and rubber industries
Subjects
Details
- Language :
- English
- ISSN :
- 10920110
- Volume :
- 265
- Issue :
- 1
- Database :
- Gale General OneFile
- Journal :
- Chemical Market Reporter
- Publication Type :
- Periodical
- Accession number :
- edsgcl.118985034